Efficacy Versus Effectiveness: The HORIZON‐Pivotal Fracture Trial and Its Emulation in Claims Data
Primary result · Hip fracture riskResult — go to the resultHazard ratio 0.72 95% CI 0.51–0.92Authors' conclusion
Real-world emulation of the HORIZON-PFT found that zoledronic acid reduced hip fractures risk over an 18-month follow-up period.
Study context
- Population
- Women with osteoporosis meeting HORIZON-PFT eligibility criteria, two US claims databases, August 2007 to December 2020 or June 2021
- Comparison
- Zoledronic acid vs raloxifene
- Primary endpoint
- Hip fracture
- Follow-up
- 18 months
Methodological detailsUS claims databases, active comparator (raloxifene as proxy for placebo), prespecified agreement metrics, protocol registered before inferential analyses, on-treatment follow-up truncated at 18 months, Original HORIZON-PFT: HR 0.59 (95% CI 0.42-0.83) for hip fracture over 3 years
- US claims databases
- Active comparator (raloxifene as proxy for placebo)
- Prespecified agreement metrics
- Protocol registered before inferential analyses
- On-treatment follow-up truncated at 18 months
- Original HORIZON-PFT: HR 0.59 (95% CI 0.42-0.83) for hip fracture over 3 years
Primary result
Hip fracture risk
Hazard ratio
0.72
95% CI 0.51–0.92
Zoledronic acidvs Raloxifene
HR 0.72 (95% CI 0.51–0.92)
As reported in the abstract
Further findings
| Outcome | HR |
|---|---|
| Interpolated HORIZON-PFT effect on hip fracture at 18 months (HR RCT)Zoledronic acid vs Placebo · interpolated estimate; nearly identical to database HR 0.72 | 0.74 |
Hip fracture risk after 18 months, trial vs database
- Trial
- 9.3 in 1,000
- Database analysis
- 8.3 in 1,000
Original publication
Efficacy Versus Effectiveness: The HORIZON‐Pivotal Fracture Trial and Its Emulation in Claims Data. Arthritis Rheumatol. Published 18 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →